Ionis Pharmaceuticals: Q2 Earnings Snapshot

IONIS PHARMACEUTICALS INC (IONS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20078953_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ionis reports second quarter 2026 financial results and highlights progress on key programs - TRYNGOLZA ® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large p

Ionis Pharmaceuticals (IONS) said its late-stage CARDIO TTRansform trial of eplontersen with AstraZeneca did not meet the primary efficacy endpoint, prompting a sharp share drop and a shareholder investigation. The stock was down 26.1% over 30 days and 29.0% YTD. The article cites a $92 fair value versus $56.55 last close and discusses valuation metrics including P/S 8.8x.

Ionis Pharmaceuticals (NASDAQ: IONS) shares fell about 23% on July 9, 2026 after it and AstraZeneca reported the Phase 3 CARDIO-TTRansform trial of eplontersen for ATTR-CM did not meet the primary efficacy endpoint. The company said adding eplontersen was not statistically beneficial in a contemporary standard-of-care population. Hagens Berman opened an investor-fraud investigation into trial transparency.

Biogen reported at the Alzheimer’s Association International Conference that its experimental antisense drug diranersen, given via spinal injection, slowed cognitive decline in a subset of about 400 participants with mild cognitive impairment or mild Alzheimer’s. In one lowest-dose test, results showed a 26% reduction in decline versus placebo. Biogen plans a larger study; side effects included injection pain and temporary confusion.

Ionis Pharmaceuticals (IONS) shares fell sharply after two consecutive setbacks. On July 9, Ionis and AstraZeneca said the Phase 3 eplontersen (Wainua) trial for ATTR-CM failed its primary goal. On July 10, Roche ended two Huntington’s programs with Ionis, including tominersen. IONS dropped about 24% then another 8%, while analysts cut price targets but largely kept Buy ratings.

Ionis Pharmaceuticals (IONS) shares fell about 9% after its ATTR-CM trial with AstraZeneca reported that adding eplontersen to standard of care did not significantly reduce cardiovascular death and recurrent events through Week 140 versus placebo. Most patients used transthyretin stabilizers at baseline, and analysts said existing therapies may benefit despite the result.